Previous 10 | Next 10 |
ANN ARBOR, Mich., April 12, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report first quarter 2021 financial results after the close of the U.S. financial markets on Tuesday, May 4, 2021. Following the release, company management will host a webcast and co...
ANN ARBOR, Mich., April 06, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat at the 20 th Annual Needham Virtual Healthcare Conference on Tuesday, April 13, 202...
Esperion (ESPR) announces results of a Phase 2 study evaluating the combination of NEXLETOL (bempedoic acid) 180 mg Tablet, ezetimibe 10 mg and atorvastatin 20 mg in patients with hypercholesterolemia showed reduction in low-density lipoprotein cholesterol ((LDL-C)) levels by 60.5% vs. p...
- Results of bempedoic acid, ezetimibe and atorvastatin triple therapy study published in March issue of Atherosclerosis - - Combining three orally administered once-daily LDL-C lowering medicines has not been previously studied, though combination therapy is common in other are...
Esperion's share price has bounced up and down during 2020 while its short interest skyrocketed. Esperion has launched two new therapies, Nexletol and Nexlizet, in the teeth of the pandemic. To a great extent it has managed the launch as a telehealth endeavor. Esperion's ex-US...
Image source: The Motley Fool. Esperion Therapeutics Inc (NASDAQ: ESPR) Q4 2020 Earnings Call Feb 23, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Esperion Therapeutics Inc (ESPR) Q4 2020 Earnings Call Transcript...
Esperion Therapeutics, Inc. (ESPR) Q4 2020 Earnings Conference Call February 23, 2021, 16:30 ET Company Participants Benjamin Church - Head, Corporate Communications & IR Timothy Mayleben - President, CEO & Director Sheldon Koenig - COO Richard Bartram - CFO & Corporate Secretary ...
Esperion Therapeutics (ESPR): Q4 GAAP EPS of -$3.89 misses by $0.16.Revenue of $9.64M (+883.7% Y/Y) misses by $2.88M.As of Dec. 31, 2020, cash, equivalents and investment securities available-for-sale totaled $305M.2021 Outlook: R&D expenses to be $120-$130M; S, G&A expenses of $...
Fourth Quarter 2020 U.S. Product Revenue of $8.2 Million, Approximately 150 Percent Increase Compared to the Third Quarter Over 21,000 Patients on NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Tablets in the U.S. CLEAR Outcomes...
Esperion Therapeutics (ESPR) is trading ~3.9% lower in premarket after Goldman Sachs downgraded the stock to sell from neutral, citing the potential headwinds to the market launch of Nexletol/Nexlizet.The price target was lowered to $24 from $44 per share, implying a ~34.9% downside...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
ANN ARBOR, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financi...
ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET. Esperion Therapeutics At Esperion, we discover, develop, and commercialize innovat...
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls &...